Exact Sciences (NASDAQ:EXAS) shares could get a lot healthier if its test aimed at early...

Exact Sciences (NASDAQ:EXAS) shares could get a lot healthier if its test aimed at early detection of colon cancer really works, Barron's writes. If the trial results, expected early next year, are favorable, the test could hit the market in 2014 and the company's annual revenue could top $500M or even $1B by the end of this decade if the test gains wide acceptance. EXAS +7.5% premarket.